American Medical Association Grants PreludeDx™ a CPT PLA Code for Proprietary DCISionRT® Test

LAGUNA HILLS, Calif.: LAGUNA HILLS, Calif., Nov. 10, 2021 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that the American Medical Association (AMA) has issued a new, dedicated Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) code for DCISionRT®,...

Click to view original post